A Phase III trial of ST-62516 to improve cardiorenal outcomes in patients undergoing percutaneous coronary intervention (PCI)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 19 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

11 Nov 2024 According to a Saghmos Therapeutics media release, company poised to enter a Phase 3 study of ST-62516 (trimetazidine) to reduce the risk of cardiorenal complications after PCI, announced its participation at the UBS Global Healthcare Conference.
17 Sep 2024 According to a Saghmos Therapeutics media release, company poised to enter a Phase 3 study of ST-62516
05 Jun 2024 According to a Saghmos Therapeutics media release, company announced Issuance of U.S. Patent for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com